This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
by Zacks Equity Research
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
by Zacks Equity Research
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
by Zacks Equity Research
Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
by Zacks Equity Research
The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
by Zacks Equity Research
Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
by Zacks Equity Research
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics
by Zacks Equity Research
Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.
Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod
by Zacks Equity Research
Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
by Zacks Equity Research
Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 44.12% and 9.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.85% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 51.61% and 29.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Solid Biosciences Inc. (SLDB) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion
by Zacks Equity Research
Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.
CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug
by Zacks Equity Research
CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.
Gilead (GILD), RCUS Announce Positive Data From NSCLC Study
by Zacks Equity Research
Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).
Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA
by Zacks Equity Research
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.63% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 5.36% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -3.78% and 4.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Albireo Pharma (ALBO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Albireo Pharma (ALBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.